Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

The Trust Test

Innovative Medical Solutions for Postponing and Undoing Age-Related Disease

Aubrey de Grey, Chief Science Officer at SENS Research Foundation, discusses a range of interesting topics surrounding innovative interventions and technologies that could not just postpone, but theoretically reverse, age-related...

Impetus Digital

- PMLiVE

Almirall and Evotec team up in multi-target dermatology alliance

The companies will focus on developing novel therapies for chronic skin diseases and skin cancer

- PMLiVE

Moderna wins Prix Galien UK Award for best biotechnology product

The Prix Galien Awards ceremony was held at the National History Museum in London

Why testing shouldn’t be confined to the lab

Believe it or not, experiments are just as important in marketing as they are in science.

Dice Medical Communications

- PMLiVE

Almirall and Inserm Transfert to develop innovative vitiligo treatments

Vitiligo is a chronic skin condition that affects patients worldwide

- PMLiVE

Recognising HIV Vaccine Awareness Day

HIV Vaccine Awareness Day is on 18 May

- PMLiVE

AstraZeneca and UK-based biotech company RQ BIO sign licencing agreement

RQ BIO has developed a portfolio of early-stage monoclonal antibodies targeting SARS-CoV-2

- PMLiVE

Boehringer Ingelheim’s pulmonary fibrosis treatment produces promising phase 2 data

The potential new oral treatment showed a reduction in lung function decline

- PMLiVE

NICE recommends AstraZeneca’s Imfinzi for adults with non-small cell lung cancer

The treatment will be available for eligible patients in England with a stage 3 diagnosis

- PMLiVE

FREE Live Webinar – Accelerating Patient recruitment in Clinical Trials post COVID-19 – 8th June 2022

Innovative Trials and Parexel invite you to attend the live webinar

Innovative Trials

- PMLiVE

Phase 3 trial of AstraZeneca and Avillion’s PT027 shows promise for asthma patients

Results of MANDALA trial will be presented at the American Thoracic Society (ATS) 2022 International Conference

- PMLiVE

MHRA approves Infex Therapeutics’s study for treatment for non-cystic fibrosis patients

The treatment, for Pseudomonas aeruginosa, will address a chronic and debilitating respiratory condition that has no approved available treatments

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links